skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Table of Contents

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Appendix B: Acronyms

(Last updated: February 12, 2014; last reviewed: February 12, 2014)

Appendix B: Acronyms
Acronym/Abbreviation
Full Name
3TC lamivudine
AAP American Academy of Pediatrics
ABC
abacavir
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANC
absolute neutrophil count
ART
antiretroviral therapy
ARV
antiretroviral
AST
aspartate aminotransferase
ATV
atazanavir
ATV/r
ritonavir-boosted atazanavir
AUC
area under the curve
AV
atrioventricular
BMD
bone mineral density
BMI
body mass index
BUN
blood urea nitrogen
cART
combination antiretroviral therapy
CBC
complete blood count
CDC
Centers for Disease Control and Prevention
CHER Trial
The Children with HIV Early Antiretroviral Therapy Trial
CHIPS
Collaborative HIV Pediatric Study
CK
creatine kinase
Cmax
maximum plasma concentration
Cmin
minimum plasma concentration
CMV
cytomegalovirus
CNS
central nervous system
COBI
cobicistat
CPK creatine phosphokinase
CrCl
creatinine clearance
CT
computed tomography
CVD
cardiovascular disease
CYP
cytochrome P
D/M
dual-mixed (tropic)
d4T
stavudine
ddI
didanosine
DM
diabetes mellitus
DMPA
depot medroxyprogesterone acetate
DOT
directly observed therapy
DRESS
drug rash with eosinophilia and systemic symptoms
DRV
darunavir
DRV/r
ritonavir-boosted darunavir
DXA
dual-energy x-ray absorptiometry
EBV
Epstein-Barr virus
EC
enteric-coated
ECG
electrocardiogram
EFV
efavirenz
ELISA
enzyme-linked immunosorbent assay
EM
erythema multiforme
ENF, ENV enfuvirtide
ETR, ETV etravirine
EVG elvitegravir
FDA
Food and Drug Administration
FPG
fasting plasma glucose
FPV
fosamprenavir
FPV/r
ritonavir-boosted fosamprenavir
FTC
emtricitabine
FXB
François-Xavier Bagnoud Center
G6PD
glucose-6-phosphate dehydrogenase
G-CSF
granulocyte colony-stimulating factor
GGT
gamma glutamyl transpeptidase
GI
gastrointestinal
GIQ
genotypic inhibitory quotient
HAART
highly active antiretroviral therapy
HAV
hepatitis A virus
HBV
hepatitis B virus
HCV
hepatitis C virus
HDL
high-density lipoprotein
HDL-C
high-density lipoprotein cholesterol
Hgb
hemoglobin
HHS
U.S. Department of Health and Human Services
HIVMA
HIV Medicine Association
HPPMCS
HIV Paediatric Prognostic Markers Collaborative Study
HRSA
Health Resources and Services Administration
HSR
hypersensitivity reaction
HSV
herpes simplex virus
IAS-USA
International Antiviral Society-USA
IC50
mean inhibitory concentration
ICH
intracranial hemorrhage
IDSA
Infectious Diseases Society of America
IDV
indinavir
IFA assay
immunofluorescent antibody assay
IgE
immunoglobulin E
INSTI
integrase strand transfer inhibitor
IQ
inhibitory quotient
IRIS
immune reconstitution inflammatory syndrome
IU
international units
IUD
intrauterine device
IV
intravenous/intravenously
IVIG
intravenous immune globulin
LDL
low-density lipoprotein
LDL-C
low-density lipoprotein cholesterol
LFT
liver function test
LIP
lymphoid interstitial pneumonia
LPV
lopinavir
LPV/r
ritonavir-boosted lopinavir
MAC
Mycobacterium avium complex
m-DOT
modified directly observed therapy
MEMS
Medication Event Monitoring System
MRI
magnetic resonance imaging
msec
milliseconds
MVC
maraviroc
NA-ACCORD
North American AIDS Cohort Collaboration on Research and Design
NFV
nelfinavir
NIH
National Institutes of Health
NNRTI
non-nucleoside reverse transcriptase inhibitor/non-nucleoside analogue reverse transcriptase inhibitor
non-HDL-C
non-high-density lipoprotein cholesterol
NRTI
nucleoside reverse transcriptase inhibitor/nucleoside analogue reverse transcriptase inhibitor
NVP
nevirapine
OARAC
Office of AIDS Research Advisory Council
OBR
optimized background regimen
OBT
optimized background therapy
OGTT
oral glucose tolerance test
OI
opportunistic infection
PBMC
peripheral blood mononuclear cells
PCP
Pneumocystis jiroveci pneumonia
PCR
polymerase chain reaction
PENTA
Paediatric European Network for Treatment of AIDS
PG
plasma glucose
Pgp
p-glycoprotein
PI
protease inhibitor
PIDS
Pediatric Infectious Diseases Society
PK
pharmacokinetic
PPI
proton-pump inhibitor
PR
protease
PUFA
polyunsaturated fatty acid
RAL
raltegravir
RBV
ribavirin
RPG
random plasma glucose
RPV
rilpivirine
RT
reverse transcriptase
RTV
ritonavir
SJS
Stevens-Johnson syndrome
SQ
subcutaneous
SQV
saquinavir
STI
structured treatment interruptions
T-20
enfuvirtide
TB
tuberculosis
TC
total cholesterol
TDF
tenofovir disoproxil fumarate
TDM
therapeutic drug monitoring
TEN
toxic epidermal necrolysis
TG
triglyceride
THAM
tris–hydroxymethyl-aminomethane
TMP-SMX
trimethoprim sulfamethoxazole
TPV
tipranavir
TPV/r
ritonavir-boosted tipranavir
UA
urinalysis
UGT1A1
uridine diphosphate glucoronosyltransferase
ULN
upper limit of normal
USPHS
U.S. Public Health Service
WHO
World Health Organization
ZDV
zidovudine

Back to Top